Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular and Structural Mechanism of Pan-Genotypic HCV NS3/4A Protease Inhibition by Glecaprevir.

ACS chemical biology - 21 Feb 2020

Timm Jennifer, Kosovrasti Klajdi, Henes Mina, Leidner Florian, Hou Shurong, Ali Akbar, Kurt Yilmaz Nese, Schiffer Celia A

Abstract excerpt

Hepatitis C virus, causative agent of chronic viral hepatitis, infects 71 million people worldwide and is divided into seven genotypes and multiple subtypes with sequence identities between 68 to 82%. While older generation direct-acting antivirals had varying effectiveness against different genotypes, the newest NS3/4A protease inhibitors including glecaprevir (GLE) have pan-genotypic activity. The structural...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amides
Share to Aminoisobutyric Acids

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carbamates

Share to Cyclopropanes

Share to Lactams, Macrocyclic

Share to Quinoxalines

Share to Serine Proteases

Share to Serine Proteinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 31868341
DOI: 10.1021/acschembio.9b00675
PMCID: PMC7747061

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular and Structural Mechanism of Pan-Genotypic HCV NS3/4A Protease Inhibition by Glecaprevir.PMID 31868341Read ↗

Molecular and Dynamic Mechanism Underlying Drug Resistance in Genotype 3 Hepatitis C NS3/4A Protease.Semantic proximity Read ↗

In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir.Semantic proximity Read ↗

Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding.Semantic proximity Read ↗

The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease InhibitorsSemantic proximity Read ↗

Avoiding Drug Resistance by Substrate Envelope-Guided Design: Toward Potent and Robust HCV NS3/4A Protease Inhibitors.Semantic proximity Read ↗

A Database-Derived Global Overview of HCV Resistance-Associated Substitutions: Characterizing Genotypic, Regional, and Temporal Heterogeneity.Semantic proximity Read ↗

Resistance mutations against HCV protease inhibitors and antiviral drug design.Semantic proximity Read ↗

GSK2818713, a Novel Biphenylene Scaffold-Based Hepatitis C NS5A Replication Complex Inhibitor with Broad Genotype Coverage.Semantic proximity Read ↗

Hepatitis C RNA-dependent RNA polymerase inhibitors: a review of structure-activity and resistance relationships; different scaffolds and mutations.Semantic proximity Read ↗

Characterization of HCV resistance from a 3-day monotherapy study of voxilaprevir, a novel pangenotypic NS3/4A protease inhibitor.Semantic proximity Read ↗

Cross-genotypic examination of hepatitis C virus polymerase inhibitors reveals a novel mechanism of action for thumb binders.Semantic proximity Read ↗

Discovery of daclatasvir, a pan-genotypic hepatitis C virus NS5A replication complex inhibitor with potent clinical effect.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.